The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United Therapeutics (NASDAQ:UTHR).
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Amgen (NASDAQ:AMGN) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Vertex Pharmaceuticals (NASDAQ:VRTX) and the rest of the therapeutics stocks fared in Q3.
Could Halozyme Therapeutics be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing what investors need to know.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Halozyme Therapeutics has had an impressive run over the past six months as its shares have beaten the S&P 500 by 24.3%. The stock now trades at $75.77, marking a 35.8% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.1% year on year to $354.3 million. The company’s full-year revenue guidance of $1.34 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $1.72 per share was 5.5% above analysts’ consensus estimates.
